iRegene Therapeutics Raises 210M Yuan in Series C1 for AI-Powered Cell Therapy Platform

iRegene Therapeutics has successfully completed a Series C1 financing round, raising 210 million yuan ($29 million). This funding, co-led by Guanghe Capital and Xingze Capital, will enhance the company's clinical pipeline and upgrade its AI-driven platform. The funds will also support scaled manufacturing capabilities and international partnerships, crucial for advancing its product offerings. iRegene's proprietary platform addresses key challenges in traditional cell therapy manufacturing, enabling efficient production of functional cells.